Cerebrovascular Reactivity to Acetazolamide in Stable COPD Patients
Journal of Clinical Medicine · 01.12.2025 · 14 (23) · 8535
DOI: 10.3390/jcm14238535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.12.2025. Verfasst von Péter Siró und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: COPD
Abstract (Originalsprache)
Background
COPD patients may be prone to cerebral small vessel disease resulting in perivascular white matter lesions and consequent cognitive decline. The pathophysiological background of these observations is not completely understood. It is hypothesized that COPD may involve systemic vascular dysfunction extending to the brain. The present study aimed to assess whether acetazolamide-induced cerebral vasoreactivity and cerebrovascular reserve capacity are impaired in patients with COPD.
Methods
A total of 17 patients with COPD and 20 healthy control subjects underwent transcranial Doppler monitoring before and after IV administration of 15 mg/kgBW acetazolamide for 20 min. Cerebrovascular reactivity (CVR) was defined as a percent increase in blood flow velocity in the middle cerebral artery (MBFV) after acetazolamide. Cerebrovascular reserve capacity (CVRC) was defined as the maximal percent change in MBFV during the entire registration.
Results
Administration of acetazolamide resulted in a slight decrease in pH and a mild increase in PaCO2 (both p < 0.001) in COPD patients. Absolute MBFV values were consequently higher, and pulsatility indices were lower in control subjects compared to those measured in patients with COPD. The CVR at different time points after acetazolamide and CVRC did not show any difference between COPD patients and control subjects.
Conclusions
In the present study, in normocapnic mild and normocapnic moderate COPD patients, cerebrovascular reactivity is not impaired, indicating that in mild stages, cerebral arteriolar function is preserved. Further studies, using patient selection based on different severity stages of the disease, may show whether alteration of the cerebral arteriolar function is responsible for the white matter lesions and cognitive decline observed in severe COPD patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Department of Pulmonology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
ORCID-Profile: Béla Fülesdi
Zitieren
APA
Siró, P., Szabó-Szűcs, R., Dudás, V., Horváth, I., Fülesdi, B., & Vaskó, A. (2025). Cerebrovascular Reactivity to Acetazolamide in Stable COPD Patients. Journal of Clinical Medicine, 14(23), 8535. https://doi.org/10.3390/jcm14238535
Vancouver
Siró P, Szabó-Szűcs R, Dudás V, Horváth I, Fülesdi B, Vaskó A. Cerebrovascular Reactivity to Acetazolamide in Stable COPD Patients. Journal of Clinical Medicine. 2025;14(23):8535. doi:10.3390/jcm14238535
BibTeX
@article{Sir2025,
author = {Siró, Péter and Szabó-Szűcs, Regina and Dudás, Viktória and Horváth, Ildikó and Fülesdi, Béla and Vaskó, Attila},
title = {Cerebrovascular Reactivity to Acetazolamide in Stable COPD Patients},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {23},
pages = {8535},
doi = {10.3390/jcm14238535}
}
EUVIMED